Replies to post #3588 on Zivo Bioscience Inc (ZIVO)

[Amigo Mike]

Gumball,

At the moment I have 3 other plays I am working on. So at present not doing anything with HEPI beyond waiting. If I churn 1 or 2 of those before the annual meeting I'll consider more HEPI.

We are in September. Dahl has created some expectations for more results becoming available in September with the most recent PRs.

1. Expanded bovine invivo test that was supposed to start July 21 with expectation for results early September. Being invivo is a big deal because it should yield some indication of how well HEPI's bioactive might perform in the field.

2. Continued study results and expanded canine study challenge tests between glucosamine and HEPIs bioactive with the glucosamine results mid-lare September. I think if the bioactive performs favorably to glucosamine that could garner some attention.

3. Dahl further indicated the canine glucosamine results might lead to starting the licensing discussions for the canine vertical. So I continue to think a canine license is more likely before a bovine license. And we also do not know who HEPI has discussed a canine license with.

So I think HEPI has reached a pivotal juncture here. I could see a scenario where Dahl is late .... As usual ... Delivering results on these tests ..... But coinciding with the annual meeting and name change of the company which is slated for October 14. A month away. My opinion is that no results should be held and should be available in a timely fashion. Changing the name and establishing the identity and brand will take care of itself if they begin to sign licenses for the bioactive.

Funny, I would bet a few bucks NO ONE that posts negatively on this stock will show up at the annual meeting and sit with mgmt and constructively ask questions. I might even surmise never having spoken with mgmt or any other partner HEPI has worked with. I haven't yet decided on whether I will be going to Detroit this year. For me its all in a day's due diligence as I live close enough to Fly out early AM and Fly home in time for dinner same day.

I do believe there is a clear experience gap with mgmt understanding the public and capital markets. Ultimately, the bioactive still must perform. Mgmt must articulate the success and value the bioactive brings to the company and ultimately to shareholders. The message must be clear, concise and provide some vision into when shareholders might see the light at the end of the tunnel in order to remove the doubt that surrounds the company. And they must develop and consummate licenses as outlined in the business plan.

Amigo Mike